Ultragenyx to Present at J.P. Morgan Healthcare Conference
January 03 2019 - 8:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development of novel products for serious
rare and ultra-rare genetic diseases, today announced that Emil D.
Kakkis, M.D., Ph.D., the company's Chief Executive Officer and
President, will present at the 37th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 8, 2019 at 4:00 pm PT in San
Francisco.
The live and archived webcast of the company presentations will
be accessible from the company’s website at
http://ir.ultragenyx.com/events.cfm. The replay of the webcast will
be available for 90 days.
About Ultragenyx Pharmaceutical Inc. Ultragenyx
is a biopharmaceutical company committed to bringing to patients
novel products for the treatment of serious rare and ultra-rare
genetic diseases. The company has built a diverse portfolio of
approved therapies and product candidates aimed at addressing
diseases with high unmet medical need and clear biology for
treatment, for which there are no approved therapies.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's
website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaDanielle
Keatley
415-475-6876
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2023 to Apr 2024